✦ LIBER ✦

More on risk/benefit ratio of anti-IL-2 receptor monoclonal antibodies

✍ Scribed by Jean-Paul Soulillou; Diego Cantarovich

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunological effects of the anti-IL-2 r

✍ B Nashan; R Schwinzer; HJ Schlitt; K Wonigeit; R Pichlmayr 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 767 KB

Effect of anti-class II and interleukin-

✍ A. Górski; T. Glapiński; G. Korczak-Kowalska; M. Nowaczyk 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Long-Term Results of Monoclonal Anti-Il2

✍ A. Al Najjar; I. Etienne; P. Le Pogamp; F. Bridoux; Y. Le Meur; O. Toupance; C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Characterization of a monoclonal rat ant

✍ Glen N. Gaulton; James Bangs; Stephen Maddock; Timothy Springer; Diane D. Eardle 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 937 KB

Anti-interleukin 2 receptor monoclonal a

✍ Daniel Olive; Jérǒme Raymond; Patrice Dubreuil; Dominique Charmot; Yannick Jacqu 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 683 KB

Antitumor effect of212bismuth-conjugated

✍ Sung Hoon Kim; Robert W. Kozak; Kyeong-Soo Chung; Byung Zun Ahn 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 468 KB